Christine Waibel

Baden, AG, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Extracellular vesicles as prognostic biomarkers: results of a neoadjuvant chemoimmunotherapy clinical trial in stage IIIA (N2) non-small-cell lung cancer (SAKK 16/14).

Extracellular vesicles as prognostic biomarkers: results of a neoadjuvant chemoimmunotherapy clinical trial in stage IIIA (N2) non-small-cell lung cancer (SAKK 16/14).

Journal: Frontiers in immunology

Published: February 09, 2026

First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study.

First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study.

Journal: JTO clinical and research reports

Published: July 12, 2024

Sweet syndrome with peripheral neuropathy in a patient with metastatic clear cell renal cell carcinoma.

Sweet syndrome with peripheral neuropathy in a patient with metastatic clear cell renal cell carcinoma.

Journal: BMJ case reports

Published: April 29, 2024

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment.

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment.

Journal: JTO clinical and research reports

Published: April 17, 2024

Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy.

Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy.

Journal: Nature communications

Published: March 28, 2024

Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.

Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 01, 2023

Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.

Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 13, 2022

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 12, 2021

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 29, 2019

Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.

Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.

Journal: Hematological oncology

Published: July 17, 2019

Showing 1-10 of 10

Last Updated: 09/26/2026